By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors Guan, Lei; Lai, Dehua, filed on January 6, 2015, was made available online on July 14, 2016, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application is assigned to AIC Innovations G
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a live conference call and webcast on Thursday, August 4, 2016 at 8:00 a.m. EDT to discu
LONDON- Angle PLC on Thursday reported a widened pretax loss for its most recently ended financial year as it continued to drive the commercialisation of its liquid biopsy system Parsortix, and saw maiden revenue from the product. Separately, the company said Parsortix has been formally adopted for use in an ongoing drug trial of Synta Pharmaceutic
ANGLE plc, the specialist medtech company, today announces audited preliminary results for the year ended 30 April 2016. Sales pipeline developing in the research use market Analytical and clinical study programmes developed to progress FDA clearance for Parsortix planned initial FDA clearance in metastatic breast cancer three world-leading US canc
ANGLE plc, the specialist medtech company, is delighted to announce that its Parsortix system has been formally adopted in the ongoing European wide GANNET53 drug trial, an ovarian cancer study. The Medical University of Vienna, under the leadership of Professor Robert Zeillinger is responsible for the Companion Diagnostics part of the trial, which
INTERIM REPORT July 28, 2016 at 9.00 a.m. Biotie Therapies Corp.' s Interim Report for the reporting period January 1- June 30, 2016 Biotie Therapies Corp. announces its interim report for the six month period ended June 30, 2016. Company Highlights April- June 2016* On January 19, 2016 Biotie announced that it entered into a combination agreement
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider, PCT, with a select therapeutic development pipeline, announces today that its product candidate CLBS03 was granted Fast Track designation by the US Food and Drug Administration for the treatment of type 1 diabetes mel
NEW YORK, NY/ ACCESSWIRE/ July 28, 2016/ Newsweek magazine called NASH "The 21st Century's Looming Public Health Threat". Diabetes, a recognized epidemic in the U.S. because 29 million people live with the disease, actually pales in comparison to the number of people with NAFLD. An astonishing 67 million people in the U.S. have NAFLD.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, will report second quarter 2016 financial results after the NASDAQ Global Market close on Thursday, August 11, 2016. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to di
Chugai Pharmaceutical Co., Ltd. announced today that latest data from an ongoing Japanese Phase I/II study of emicizumab was presented at the World Federation of Hemophilia 2016 World Congress in Orlando, Florida, United States. Emicizumab was designated as a Breakthrough Therapy by the US Food and Drug Administration in September 2015.
In support of World Hepatitis Day 2016, Eiger BioPharmaceuticals, Inc., a leader in the development of therapeutics for hepatitis delta infection, announced today that it is partnering with the Hepatitis B Foundation to launch a hepatitis delta disease awareness and testing program. This dedicated hepatitis delta initiative marks the start of a..
ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical trial of the placental malaria vaccine candidate, PAMVAC. Due to the trial's staggered approach, the second evaluation allows initiation of the phase Ib clinical trial to be conducted in Benin, Africa.
Lixisenatide has been approved in the U.S. under the brand name Adlyxin TM indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, including in combination with oral anti-diabetes medication and/or basal insulin. There are an estimated 27.5 million adults with type 2 diabetes in the U.S., and the U.S market co
PARIS- Sanofi said that the U.S. Food and Drug Administration approved Adlyxin or lixisenatide, a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. Commercial launches include most EU countries, Japan, Brazil, Mexico and India. The approval of Adlyxin
Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of proprietary oncolytic vaccinia virus for immunotherapy of cancers, today announced that it has initiated two new Phase 1 b clinical trials of its lead oncolytic virotherapy GL-ONC1 with leading oncology institutions, Florida Hospital Cancer Institute in.
Research and Markets has announced the addition of the "Global Radiopharmaceuticals Market Outlook 2020" report to their offering. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Owing to the production of Mo-99 by the Canada and continuous research activities in different clinical institutes in USA such as Na
International Stem Cell Corporation, a California- based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the first patient in the previously announced Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for
Statistically Significant Results Across Key Glycemic Endpoints. Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today reported additional data from the recently concluded Phase IIb trial of its oral insulin capsule ORMD-0801 in adults with type 2 diabetes. Roy Eldor, Oramed's Chief Medical Director, "We look forward to prep
Oslo, 28 July 2016- PCI Biotech a cancer focused Norwegian biopharmaceutical company, reported today that the first-in-man Phase I study with PCI Biotech's proprietary drug fimaporfin performed at University College Hospital in London in patients with various advanced solid tumours has been published in Lancet Oncology, the premier publication...
Pluristem Therapeutics Inc. has today announced its intentions to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture, which is the most common form of hip fracture...
SAN DIEGO and SHENZHEN, China, July 28, 2016/ PRNewswire/ Profil Institute for Clinical Research, Inc., a science-driven clinical research organization focused exclusively on metabolic diseases, announced today a strategic master services agreement with Shenzhen HighTide Biopharmaceutical Ltd., a subsidiary of Shenzhen Hepalink Pharmaceutical Co.
TAURx phase 3 trial results announced. Phase three trials for a drug which targets Alzheimer's disease developed by a company spun out of the University of Aberdeen have shown promising results. TauRx Therapeutics Ltd, a member of the TauRx Pharmaceuticals group which is developing technology with the aim of developing new treatments and diagnostic
Raptor Pharmaceutical Corp. today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Raptor's R&D pipeline includes RP103, known commercially as PROCYSBI , for Huntington's disease and mitochondrial disorders, including Leigh syndrome. Raptor holds several orphan drug..
Researchers from Harvard School of Medicine Detail Findings in Breast Cancer. By a News Reporter-Staff News Editor at Women's Health Weekly Current study results on Oncology have been published. Our news journalists obtained a quote from the research from the Harvard School of Medicine, "The highly selective oral CDK 4/ 6 inhibitors palbociclib,
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Majano, Romeo, filed on February 17, 2016, was made available online on July 14, 2016. No assignee for this patent application has been made. Nevertheless, in recent years, non-surgical